Track F

F8 Dos and Don'ts of Alliances and Large Partnerships with Pharma

Track: Global Issues

Target Audience: Advanced

John S. Swartley, University of Pennsylvania

James W. Bowen, University of Pennsylvania
David Brush, Johnson & Johnson Innovation
Karin Immergluck, University of California, San Francisco (UCSF)
Lauren Murdza, DLA Piper LLP

For the past few decades, academic-industry collaborations have generally been comprised of agreements with individual investigators at specific universities. More recently, this process has metamorphosized into multi-party agreements. Pharma has established alliances with entire departments, multiple departments or schools within the same university or even multiple universities and research centers. Academic-pharma alliances now fit many models. In this session, we will discuss early lessons gleaned from these academia-pharma partnerships. Learn what makes an alliance succeed or fail and what needs to be taken into account when entering into a collaboration or alliance agreement.

Return to Schedule

AUTM 2017 Annual Meeting Sponsors